28191654|t|Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study
28191654|a|There is a lack of nationwide studies examining the epidemiology and comorbidities of psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) in Asian populations. The purpose of this study is to determine the demographics of psoriasis in Korea along with the incidence of cerebro - cardiovascular (CV) comorbidities and to compare these risks between populations with PsA and with PsV. This cohort study identified 15 484 patients with psoriasis among 855 003 subjects in the Korean National Health Insurance Database from 2002 through 2010. The cases were further classified into PsA and PsV. We used hazard ratios (HR) and 95% confidence intervals (CI) from the univariate and age - sex adjusted logistic regression model to assess the risk of comorbidities in patients with PsA and PsV. The annual prevalence of psoriasis increased from 313.2 to 453.5/100 000 people from 2002 through 2010; however, the overall incidence rate for psoriasis slightly decreased (252.7-212.6/100 000 population). Of psoriatic patients, 10.8% had PsA, and after adjusting for age and sex, PsA patients had a significantly higher risk of dyslipidemia than PsV patients (adjusted HR, 1.185; 95% CI, 1.049-1.338). When stratified by age group, subjects aged 20-39 years had a higher risk of stroke and many CV risk factors. In conclusion, the prevalence of psoriasis, while within the range of previous reports, tended to increase over time. Patients with PsA had higher burdens of specific comorbid diseases than those with PsV, especially at a comparatively early age.
28191654	0	12	Epidemiology	T169	C0014508
28191654	17	31	cardiovascular	T047	C0007222
28191654	32	45	comorbidities	T078	C0009488
28191654	49	57	patients	T101	C0030705
28191654	63	72	psoriasis	T047	C0033860
28191654	76	110	Korean nationwide population-based	T098	C1556095
28191654	111	123	cohort study	T081	C0009247
28191654	135	139	lack	T080	C0332268
28191654	143	153	nationwide	T082	C0681788
28191654	154	161	studies	T062	C2603343
28191654	162	171	examining	T033	C0332128
28191654	176	188	epidemiology	T169	C0014508
28191654	193	206	comorbidities	T078	C0009488
28191654	210	228	psoriasis vulgaris	T047	C0263361
28191654	230	233	PsV	T047	C0263361
28191654	239	258	psoriatic arthritis	T047	C0003872
28191654	260	263	PsA	T047	C0003872
28191654	268	273	Asian	T098	C0078988
28191654	274	285	populations	T098	C1257890
28191654	291	298	purpose	T169	C1285529
28191654	319	328	determine	T080	C0521095
28191654	333	345	demographics	T090	C0011298
28191654	349	358	psoriasis	T047	C0033860
28191654	362	367	Korea	T083	C0022771
28191654	383	392	incidence	T081	C0021149
28191654	396	403	cerebro	T047	C0007820
28191654	406	420	cardiovascular	T047	C0007222
28191654	422	424	CV	T047	C0007222
28191654	426	439	comorbidities	T078	C0009488
28191654	447	454	compare	T052	C1707455
28191654	461	466	risks	T058	C0086930
28191654	475	486	populations	T098	C1257890
28191654	492	495	PsA	T047	C0003872
28191654	505	508	PsV	T047	C0263361
28191654	515	527	cohort study	T081	C0009247
28191654	528	538	identified	T080	C0205396
28191654	546	554	patients	T101	C0030705
28191654	560	569	psoriasis	T047	C0033860
28191654	584	592	subjects	T096	C0681850
28191654	600	606	Korean	T098	C1556095
28191654	607	632	National Health Insurance	T058	C0027452
28191654	633	641	Database	T170	C0242356
28191654	670	675	cases	T169	C0868928
28191654	681	688	further	T082	C1517331
28191654	689	699	classified	T185	C0008902
28191654	705	708	PsA	T047	C0003872
28191654	713	716	PsV	T047	C0263361
28191654	726	739	hazard ratios	T081	C2985465
28191654	741	743	HR	T081	C2985465
28191654	753	773	confidence intervals	T081	C0009667
28191654	775	777	CI	T081	C0009667
28191654	788	798	univariate	T062	C0683962
28191654	803	806	age	T032	C0001779
28191654	809	812	sex	T032	C1522384
28191654	822	847	logistic regression model	UnknownType	C0681925
28191654	851	866	assess the risk	T058	C0086930
28191654	870	883	comorbidities	T078	C0009488
28191654	887	895	patients	T101	C0030705
28191654	901	904	PsA	T047	C0003872
28191654	909	912	PsV	T047	C0263361
28191654	918	924	annual	T079	C0332181
28191654	925	935	prevalence	T081	C0220900
28191654	939	948	psoriasis	T047	C0033860
28191654	949	958	increased	T081	C0205217
28191654	987	993	people	T098	C0027361
28191654	1039	1053	incidence rate	T081	C1708485
28191654	1058	1067	psoriasis	T047	C0033860
28191654	1068	1086	slightly decreased	T081	C0205216
28191654	1108	1118	population	T098	C1257890
28191654	1124	1133	psoriatic	T047	C0033860
28191654	1134	1142	patients	T101	C0030705
28191654	1154	1157	PsA	T047	C0003872
28191654	1183	1186	age	T032	C0001779
28191654	1191	1194	sex	T032	C1522384
28191654	1196	1199	PsA	T047	C0003872
28191654	1200	1208	patients	T101	C0030705
28191654	1215	1228	significantly	T078	C0750502
28191654	1229	1240	higher risk	T033	C3843761
28191654	1244	1256	dyslipidemia	T047	C0242339
28191654	1262	1265	PsV	T047	C0263361
28191654	1266	1274	patients	T101	C0030705
28191654	1285	1287	HR	T081	C2985465
28191654	1300	1302	CI	T081	C0009667
28191654	1323	1333	stratified	T080	C0205363
28191654	1337	1346	age group	T100	C0027362
28191654	1348	1361	subjects aged	T032	C2348575
28191654	1368	1373	years	T079	C0439234
28191654	1380	1391	higher risk	T033	C3843761
28191654	1395	1401	stroke	T047	C0038454
28191654	1411	1413	CV	T047	C0007222
28191654	1414	1426	risk factors	T033	C0035648
28191654	1447	1457	prevalence	T081	C0220900
28191654	1461	1470	psoriasis	T047	C0033860
28191654	1489	1494	range	T081	C1514721
28191654	1498	1506	previous	T079	C0205156
28191654	1507	1514	reports	T170	C0684224
28191654	1526	1534	increase	T169	C0442805
28191654	1535	1544	over time	T079	C0040223
28191654	1546	1554	Patients	T101	C0030705
28191654	1560	1563	PsA	T047	C0003872
28191654	1568	1582	higher burdens	T078	C2828008
28191654	1595	1612	comorbid diseases	T047	C0012634
28191654	1629	1632	PsV	T047	C0263361
28191654	1650	1663	comparatively	T080	C0205556
28191654	1664	1673	early age	T032	C0001779